Karman Space & Defense to Present at the William Blair 45th Annual Growth Stock Conference
Conference Presentation Details:
Time: 11:20 a.m. CT (12:20 p.m. ET)
Webcast link: https://event.summitcast.com/view/d33hYDasjRy97oS2SZxBz4/X8J3UbvVfKy2wxxBmHy6NT
The audio portion of Karman's presentation will be broadcast live, and a replay will be available for six months at the link above, and on the investor relations section of the company's investor website at https://investors.karman-sd.com/.
ABOUT KARMAN SPACE & DEFENSE
We specialize in the rapid design, development, and production of next-generation technologies to combat near-peer nation state threats, focused on critical, integrated systems for the hypersonic, missile defense, UAV and space sectors. Our core technology offerings include propulsion, deployable shrouds, launchers, and energetic subsystems. Customers choose our advanced solutions to deliver mission success across a diverse set of existing and emerging programs supporting high-priority defense and commercial space sector initiatives. For more information, visit Karman-SD.com.
For additional media and information, please follow us
X
YouTube
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Why Arista Networks Stock Is Skyrocketing Wednesday
Arista Networks Inc. (NYSE:ANET) reported better-than-expected second-quarter financial results after markets closed on Tuesday. Revenues increased 30.4% year over year $2.21 billion, versus estimates of $2.11 billion and the management guidance of $2.1 billion. Adjusted EPS jumped to 73 cents from 53 cents a year ago, versus estimates of 65 cents. Gross margin was 65.2% in the second CFO, Chantelle Breithaupt, said, 'Non-GAAP operating income crossed $1 billion for the first time at Arista...' View more earnings on ANET Arista Networks expects third-quarter sales of $2.25 billion versus the consensus of $2.093 billion. Analysts' Reaction Following the impressive earnings report and upbeat guidance, several prominent financial institutions reiterated their positive stance on Arista Networks. Morgan Stanley maintained an Overweight rating, raising its price forecast from $120 to $125. Piper Sandler, while holding a Neutral rating, significantly increased its price forecast from $89 to $143. UBS and Goldman Sachs both maintained Buy ratings, lifting their price forecasts from $115 to $155. Keybanc upheld its Overweight rating, adjusting its price forecast from $115 to $145, while Evercore ISI Group maintained an Outperform rating, raising its forecast from $120 to $150. Needham also maintained a Buy rating, increasing its price forecast from $130 to $155. Price Action: ANET stock is trading higher by 18.1% to $139.50 at last check Wednesday. Read Next:Photo via Shutterstock Latest Ratings for ANET Date Firm Action From To Mar 2022 Wells Fargo Upgrades Equal-Weight Overweight Feb 2022 Morgan Stanley Maintains Equal-Weight Feb 2022 Wells Fargo Maintains Equal-Weight View More Analyst Ratings for ANET View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? ARISTA NETWORKS (ANET): Free Stock Analysis Report This article Why Arista Networks Stock Is Skyrocketing Wednesday originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
Amgen Stock Sinks As Market Eyes MariTide's Next Move
Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday. The US drug maker reported adjusted earnings of $6.02 per share, up 21% year over year, beating the consensus of $5.24. Amgen reported quarterly sales of $9.18 billion, up 9%, beating the Wall Street estimate of $8.87 sales grew 9%, driven by 13% volume growth, partially offset by 3% lower net selling price. Fifteen products delivered at least double-digit sales growth in the second quarter. Outlook Following the strong quarterly performance, Amgen raised fiscal year 2025 adjusted earnings guidance from $20.00-$21.20 per share to $20.20-$21.30 versus the consensus of $20.89. The company raised sales outlook from $34.30 billion-$35.70 billion to $35 billion-$36 billion versus the consensus of $35.29 billion. MariTide in Focus Despite the positive financial results, investor focus remains squarely on the company's experimental weight-loss drug, MariTide. A William Blair analyst noted that investors are 'hyper-focused' on the drug's progress. Part 2 of the Phase 2 chronic weight management study is ongoing in obese patients, with or without type 2 diabetes. Data readout is anticipated in the fourth quarter of 2025. View more earnings on AMGN A Phase 2 study investigating MariTide for type 2 diabetes is ongoing in adults with and without obesity. Data readout is anticipated in the fourth quarter of 2025. Analyst Matt Phipps of William Blair said, 'Given the trial is solely focused on the maintenance setting, we do not believe it will address the key question of tolerability that investors continue to debate.' Analyst Phipps says Amgen shares are up 15% year-to-date, although it remains volatile as investors debate clinical updates with MariTide given the significant market opportunity and competitive landscape. 'We believe Amgen has had meaningful clinical and commercial success with assets including Repatha, Evenity, Blincyto, Tezspire, Imdelltra, and Uplizna that support continued upside on top of the potentially differentiated profile of MariTide, and therefore reiterate our Outperform rating.' Amgen has some near-term headwinds from legacy products, including the recent launch of a biosimilar to Prolia and Xgeva at the end of May 2025 (recent settlement with Sandoz), and the difficulties in gaining more market share with the biosimilar franchises, but the analyst believes clinical catalysts over the next 6 to 12 months will provide meaningful reasons for investor excitement about the long-term growth prospects of the company. Check out . Price Action: AMGN stock is trading lower by 5.10% to $284.97 at last check Wednesday. Read Next:Photo by JHVEPhoto via Shutterstock Latest Ratings for AMGN Date Firm Action From To Feb 2022 Morgan Stanley Maintains Equal-Weight Feb 2022 Wells Fargo Maintains Equal-Weight Feb 2022 Barclays Maintains Equal-Weight View More Analyst Ratings for AMGN View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? AMGEN (AMGN): Free Stock Analysis Report This article Amgen Stock Sinks As Market Eyes MariTide's Next Move originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Business Wire
24 minutes ago
- Business Wire
Northern Trust Leaders to Participate in Barclays Global Financial Services Conference on September 9 th
CHICAGO--(BUSINESS WIRE)--Northern Trust Corporation announced today that Chief Financial Officer David Fox and Chief Operating Officer Peter Cherecwich will participate in the Barclays Global Financial Services Conference in New York City on Tuesday, September 9, 2025, at 4:15 p.m. (ET). A live webcast of the event may be accessed via Northern Trust's website ( in the investor relations section. A replay will be available for approximately four weeks after the session date. About Northern Trust Northern Trust Corporation (Nasdaq: NTRS) is a leading provider of wealth management, asset servicing, asset management and banking to corporations, institutions, affluent families and individuals. Founded in Chicago in 1889, Northern Trust has a global presence with offices in 24 U.S. states and Washington, D.C., and across 22 locations in Canada, Europe, the Middle East and the Asia-Pacific region. As of June 30, 2025, Northern Trust had assets under custody/administration of US$18.1 trillion, and assets under management of US$1.7 trillion. For more than 135 years, Northern Trust has earned distinction as an industry leader for exceptional service, financial expertise, integrity and innovation. Visit us on Follow us on Instagram @northerntrustcompany or Northern Trust on LinkedIn. Northern Trust Corporation, Head Office: 50 South La Salle Street, Chicago, Illinois 60603 U.S.A., incorporated with limited liability in the U.S. Global legal and regulatory information can be found at
